Compare National Beverage Corp. (FIZZ) vs Novartis AG (NVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
National Beverage Corp. vs Novartis AG — how do they compare? National Beverage Corp. trades at $31.81 (market cap $2.89B), while Novartis AG trades at $152.36 (market cap $287.66B). The key difference: Novartis AG is far larger — about 99.5× National Beverage Corp.'s market cap, and Novartis AG pays a 3.14% dividend while National Beverage Corp. pays none. Which is the better fit depends on your goals.
| FIZZ | NVS | |
|---|---|---|
Market Cap | $2.89B | $287.66B |
Sector | Consumer Cyclical | Health |
52-Week High | $47.69 | $168.62 |
52-Week Low | $30.85 | $113.50 |
Enterprise Value | $2.60B | $327.68B |
Dividend Yield | — | 3.14% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FIZZ trades at $31.47, up 1.78% today, but faces bearish technical signals with three consecutive earnings misses. The company maintains solid profitability with 15.56% net margins and 34.03% ROE, though revenue growth has stalled at $1.2B annually. Recent news highlights a $3.25 special dividend announcement but also concerns about LaCroix brand decline and muted growth prospects.
The outlook remains cautious with analyst sentiment skewed bearish (50% sell ratings) and technical indicators pointing downward. While the dividend provides shareholder return, fundamental challenges including competitive pressures and stagnant revenue create headwinds for meaningful price appreciation in the near term.
Novartis (NVS) trades at $150.36, down 1.96% with bearish technical signals. The company maintains strong profitability with 75.38% gross margins and 23.92% net income margin, though recent earnings show mixed results with one beat and two misses. Recent acquisitions including Myricx Bio for up to $1.5 billion expand the oncology pipeline, while regulatory approvals for Itvisma and positive drug trial data support growth prospects.
While analyst consensus leans cautious with 68% hold ratings, Novartis' robust cash flow generation and strategic pipeline investments provide long-term value. Key risks include execution challenges from recent acquisitions and competitive pressures in pharmaceuticals. The stock offers stability through strong fundamentals but faces near-term technical headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About National Beverage Corp.
National Beverage Corp is one of the top 10 non-alcoholic beverage companies in the U.S. Its portfolio skews toward functional drinks (that is those purporting to offer health benefits) and is anchored by the popular LaCroix sparkling water trademark. Other offerings include Rip It energy drinks, Everfresh juices, and soda brands like Shasta and Faygo. The firm controls most of its production and distribution apparatus, with very little outsourcing. In terms of go-to-market, it uses warehouse distribution for big-box retailers, direct-store-delivery for convenience stores and other small outlets, and food-service distributors for the food-service channel (schools, hospitals, restaurants). It is controlled by chairman and CEO Nick Caporella, who owns over 73% of the common stock.
Read more on FIZZ →About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →
